Incurin Tabs [Scored 30-Blister Pack] offer a convenient, once-a-day dose to improve or eliminate estrogen-responsive urinary incontinence in female dogs. For use in spayed dogs over 1 year old.
93% of Dogs treated with INCURIN were improved or continent by 6 weeks.[Merck]
Add this item to your cart:
**Note: This product requires a veterinarian's prescription to purchase.At checkout you will need to provide your veterinarian's FAX or email address. We will then send him or her a prescription verification that he or she will need to sign and return before we can ship you this product.
* Convenient, once-daily dosing
* Same starting dose for all female dogs and just 1 tablet size in inventory
* Incurin contains Estriol, a naturally ocurring short acting estrogen found in female dogs
* Can be titrated to the lowest effective dose
* Well tolerted in clinical trials
* Safely and effectively used worldwide for over 12 years.
INCURIN tablets are indicated for the control of estrogen-responsive urinary incontinence in ovariohysterectomized female dogs.
DOSAGE AND ADMINISTRATION:
It is important to follow your veterinarian's prescription instructions for your pet.
The dose of INCURIN Tablets is not dependent upon body weight. All dogs should receive an initial dose of 2 mg INCURIN Tablets 2 tablets orally once per day for a minimum of 14 days. After urinary incontinence is controlled, the lowest effective daily dose of INCURINTablets should be determined by decreasing the dose in a step-wise manner from 2 mg once daily 2 tablets to 1 mg once daily 1 tablet, then 0.5 mg once daily 1/2 tablet depending upon the response of the individual dog. There should be a minimum of 7 days between each dose adjustment. After the lowest daily dose that controls urinary incontinence is identified, the dose may be decreased further by administering once every two days. Dogs should not receive more than 2 mg INCURIN&trade Tablets per day 2 tablets. If the dog does not respond to 2 mg of INCURIN&trade Tablets per day, the diagnosis should be re-assessed.
Human Warnings: Not for human use. Keep out of the reach of children. Women who are of child-bearing age or those who are breastfeeding should use caution when administering INCURINTablets. Wash your hands with soap and water after administration to avoid exposure to the drug. Consult a physician in case of accidental ingestion by humans.
Animal Warnings: Some estrogens have been associated with bone marrow changes and an increased risk of mammary tumors. However, target animal safety study results and foreign post-market pharmacovigilance data for INCURIN Tablets have shown that estriol-treated dogs are at low risk for developing these conditions.
Evaluation of factors contributing to urinary incontinence should be considered prior of administration of INCURIN Tablets. Do not use with other estrogens. The concomitant use of INCURIN Tablets with other estrogens has not been evaluated. The concomitant use of INCURIN Tablets with glucocorticoids has not been evaluated. The use of INCURINTablets in dogs with liver disease has not been evaluated. The safe use of INCURIN Tablets has not been evaluated in intact female dogs, pregnant or lactating dogs, male dogs, and dogs less than 1 year of age.
Incurin is contraindicated in dogs showing polyuria secondary to polydipsia, or pregnant dogs.
Some adverse reactions that could occur: anorexia, emesis, polydipsia, swollen vulva, anxiety, sexual attractiveness, somnolence, hypersalivation, estrous behavior, and mammary hyperplasia.